Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Sellig, Adare Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Oleochemical Production: a Complete Package Solution for Maximum Performance
Oleochemicals touch many parts of our daily lives – personal care, pharmaceuticals, food and more. Chemical compounds derived from natural oils and fats, oleochemicals can be used as raw materials or ingredients in a variety of applications. It comes as no surprise the market is projected to reach a global value of $54.4 billion by 2029.
Safety and Innovation: Navigating the Challenges of Antibody-Drug Conjugates
This eBook provides scientists with more information on antibody–drug conjugates (ADCs), allowing you to further your research in this field.
Advancements in Biomanufacturing: The Impact of Analytical Methods
This article collection hopes to provide scientists with more information on biopharmaceutical analytics allowing you to further your research in biomanufacturing.
Bioanalytical Breakthroughs: Advanced Chromatography in Protein Analysis and Doping Detection
With the advent of advanced chromatographic methods, researchers can now delve into the intricacies of biological samples with unparalleled precision.
Using Chemistry to Create Net-Zero Value Chains
In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
Formulating Innovative Concepts
Matthias Hofmann, Group Innovation & Technology Management Director at Azelis, provides an in-depth insight into the company’s innovation activities and the underlying market trends.
Innovation Through Formulation
Anna Bertona, Group CEO at Azelis, looks back on her first six month in this role and gives an insight into her plans for the company's development.
Sustainable Material Adoption in Industrial Sectors
IMCD Industrial Solutions surveyed top customers around the globe on their insights into eight key topics deemed pertinent to sustainability in industrial sectors. This article highlights some of the most important results.
503A Compounding – Regulatory Basis and Industry Good Practices for Pharmacies
A recently released guidance document, ISPE Guide: 503A Compounding – Regulatory Basis and Industry Good Practices for Pharmacies, summarizes and contextualizes key information from US governmental bodies relevant to 503A pharmacies.
Sponsored • Whitepaper
Transition Metals in Catalysis: From Precious to Practical
Download this complimentary Article Collection today!
E. Coli Bioprocessing: Pioneering Advances in Biotechnology
Download this complimentary Expert Insights eBook today!
The Power of qPCR in Advancing Cell & Gene Therapy Research
This Expert Insights eBook is designed to enhance scientists’ understanding of qPCR for cell and gene therapy, enabling further research in the field of drug discovery and development.
Improve Profitability And Sustainability with Activated Nickel Foam Catalysts
With foam, hydrogenation reactions are easier, more profitable and safer.
Superior Calcium Complex Greases with the Lohtragon O01 Complexing Agent
Lohtragon O01 meets the demand of today´s lubrication challenges. The calcium acetate based lubricant additive provides solutions that not only enhance the performance of calcium complex greases but also align with environmental sustainability goals.
BioProcess Forum: Cell & Gene Therapy Manufacturing
Dive into the forefront of bioprocessing evolution this March, where our expert panel explores sustainability, bioseparations, and innovation in cell and gene therapy manufacturing.
How Biotechnological Advances are Transforming Monoclonal Antibody Production
This Article Collection aims to offer scientists a wealth of information on monoclonal antibody (mAb) therapy, enabling you to advance your research in this field.
